Browsing Tag
VGA039
3 posts
Incyte stock in focus as $2bn Star Therapeutics deal nears for blood disorder pipeline
Incyte may buy Star Therapeutics for up to $2B. See why the deal matters for Jakafi risk and hematology growth.
Can VGA039 become a once-monthly standard of care for von Willebrand disease?
Star Therapeutics' VGA039 shows strong bleeding reduction across all VWD types in Phase 1/2 trial. Discover how this monthly shot could change the standard of care.
VGA039 : Vega Therapeutics begins clinical trial of Von Willebrand disease candidate
Vega Therapeutics has launched the clinical trial program for VGA039, an investigational antibody therapy for Von Willebrand disease…